RESUMEN
A rigid chiral acyclic chelator H2CHXhox was synthesized and evaluated for Ga3+-based radiopharmaceutical applications; it was compared to the previously reported hexadentate H2hox to determine the effect of a backbone reinforced from adding a chiral 1S,2S-trans-cyclohexane on metal complex stability, kinetic inertness, and in vivo pharmacokinetics. NMR spectroscopy and theoretical calculation revealed that [Ga(CHXhox)]+ showed a very similar coordination geometry to that of [Ga(hox)]+, and only one isomer in solution was observed by NMR spectroscopy. Solution studies showed that the modification results in a significant improvement in the exceptionally high thermodynamic stability of [Ga(hox)]+ with a 1.56 log unit increase in stability constant (logKML = 35.91(1)). More importantly, H2CHXhox showed very fast Ga3+ complexation at physiological pH 7.4, and acid-assisted Ga3+ complex dissociation kinetic studies (pH 1) in comparison with H2hox revealed a 50-fold increase of the dissociation half-life time from 73 min to 58 h. Fluorescence microscopy imaging study confirmed its cellular uptake and accumulation in endoplasmic reticulum and mitochondria. MTT studies indicated a quite low cytotoxicity of [Ga(CHXhox)]+ over a large concentration range. Dynamic PET imaging studies showed no accumulation in muscle, lungs, bone, and brain, suggesting no release of free Ga3+ ions. [68Ga][Ga(CHXhox)]+ is cleared from the mouse via hepatobiliary and renal pathways. Compared to [68Ga][Ga(hox)]+, the increased lipophilicity of [68Ga][Ga(CHXhox)]+ enhanced heart and liver uptake and decreased kidney clearance. [67Ga][Ga(CHXhox)]+ SPECT/CT imaging and biodistribution study revealed good clearance from liver to gallbladder after 90 min and finally into feces after 5 h. No decomposition or transchelation was observed over the 5 h study. These results confirmed H2CHXhox to be an obvious improvement over H2hox and an excellent candidate in this new "ox" family for the development of radiopharmaceutical compounds.
RESUMEN
An acyclic hexadentate oxine-derived chelating ligand, H2hox, was investigated as an alternative to current chelators for 68Ga. The straightforward preparation of H2hox, involving only one or two steps, obviates the synthetic challenges associated with many reported 68Ga chelators; it forms a Ga3+ complex of great stability (log K = 34.4) with a remarkably high gallium scavenging ability (pGa3+ = -log[Ga3+free] = 28.3, ([Ga3+] = 1 µM; [L x-] = 10 µM; pH 7.4, and 25 °C)). Moreover, H2hox coordinates 68Ga quantitatively in 5 min at room temperature in ligand concentrations as low as 1 × 10-7 M, achieving an unprecedented high molar activity of 11 ± 1 mCi/nmol (407 ± 3.7 MBq/nmol) without purification, suggesting prospective kit-based convenience. [68Ga(hox)]+ showed no decomposition in a plasma challenge. Good in vivo stability and fast renal and hepatic clearance of the [68Ga(hox)]+ complex were demonstrated using dynamic positron emission tomography/computed tomography imaging. The intrinsic fluorescence of [Ga(hox)]+ allowed for direct fluorescence imaging of cellular uptake and distribution, demonstrating the dual-channel detectability and intracellular stability of the metal complex.
Asunto(s)
Quelantes/química , Radioisótopos de Galio/química , Oxiquinolina/química , Radiofármacos/química , Animales , Ligandos , Masculino , Ratones , Modelos Moleculares , Conformación Molecular , Tomografía Computarizada por Tomografía de Emisión de Positrones , Radiofármacos/farmacocinética , Distribución TisularRESUMEN
68Ga-PSMA-11 is currently the most popular prostate-specific membrane antigen (PSMA) radioligand used in the clinic to detect prostate cancer and metastases. However, the high uptake of 68Ga-PSMA-11 in kidneys can create halo-artifacts resulting in lower detection sensitivity for lesions adjacent to the kidneys. In this study, we developed two 68Ga-labeled PSMA-targeted tracers, 68Ga-HTK01166 and 68Ga-HTK01167, based on 68Ga-PSMA-617 with the goal of improving tumor-to-kidney ratio compared to 68Ga-PSMA-11. The 2-naphthylalanine (2-Nal) in PSMA-617 was replaced with 2-indanylglycine (Igl) or 3,3-diphenylalanine (Dip) to synthesize HTK01166 and HTK01167, respectively. Binding affinities ( Ki) of Ga-PSMA-11, Ga-PSMA-617, Ga-HTK01166, and Ga-HTK01167 to PSMA were 3.13 ± 0.40, 1.23 ± 0.08, 5.74 ± 2.48, and 25.7 ± 9.84 nM, respectively, as determined by in vitro competition binding assays. 68Ga labeling was performed in HEPES buffer with microwave heating, and 68Ga-labeled PSMA-11, PSMA-617, HTK01166, and HTK01167 were obtained in 46-69% average decay-corrected radiochemical yield with >99% radiochemical purity and 62.9-152 GBq/µmol average specific activity. PET imaging and biodistribution studies were performed in mice bearing PSMA-expressing LNCap prostate cancer xenografts. All tracers enabled clear visualization of tumors in PET images with excellent tumor-to-background contrast. The uptake values (%ID/g) for tumor and kidneys at 1 h postinjection were 8.91 ± 0.86 and 204 ± 70.6 for 68Ga-PSMA-11, 16.7 ± 2.30 and 29.2 ± 5.14 for 68Ga-PSMA-617, 14.1 ± 4.40 and 147 ± 59.6 for 68Ga-HTK01166, and 7.79 ± 1.65 and 4.30 ± 1.80 for 68Ga-HTK01167. The tumor-to-kidney ratios for 68Ga-labeled PSMA-11, PSMA-617, HTK01166, and HTK01167 were 0.05 ± 0.02, 0.63 ± 0.10, 0.10 ± 0.02, and 1.98 ± 0.63, respectively. Compared with 68Ga-PSMA-617, 68Ga-HTK01166 showed comparable tumor uptake and almost 5-fold higher kidney uptake, whereas 68Ga-HTK01167 exhibited lower tumor and kidney uptake. Compared with 68Ga-PSMA-11, 68Ga-HTK01167 had similar tumor uptake and tumor-to-blood contrast ratio (23.8 ± 6.71 vs 20.4 ± 4.98) but higher tumor-to-background contrast ratios for other background organs especially for kidneys. Our data indicate that substitution of 2-Nal in PSMA-617 with other lipophilic amino acid can modulate PSMA binding affinity and their pharmacokinetics in vivo.
Asunto(s)
Antígenos de Superficie/metabolismo , Radioisótopos de Galio/farmacocinética , Glutamato Carboxipeptidasa II/metabolismo , Glicoproteínas de Membrana/farmacocinética , Compuestos Organometálicos/farmacocinética , Neoplasias de la Próstata/diagnóstico por imagen , Animales , Línea Celular Tumoral , Isótopos de Galio , Radioisótopos de Galio/administración & dosificación , Radioisótopos de Galio/química , Humanos , Riñón/metabolismo , Masculino , Glicoproteínas de Membrana/administración & dosificación , Glicoproteínas de Membrana/química , Ratones , Compuestos Organometálicos/administración & dosificación , Compuestos Organometálicos/química , Tomografía Computarizada por Tomografía de Emisión de Positrones/métodos , Tomografía de Emisión de Positrones/métodos , Próstata/diagnóstico por imagen , Próstata/patología , Neoplasias de la Próstata/patología , Distribución Tisular , Microtomografía por Rayos X/métodos , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Peptide receptors have emerged as promising targets for diagnosis and therapy. The aberrant overexpression of these receptors in different cancer subtypes allows for the adoption of new treatment strategies that complement conventional chemotherapies. Bradykinin B1 receptor (B1R) is a G protein-coupled receptor that is overexpressed in many cancers, with limited expression in healthy tissues. Previously, we developed 68Ga- and 18F-labeled derivatives of B1R antagonist peptides B9858 and B9958, and successfully targeted B1R-expressing tumor xenografts in vivo. R954 (Ac-Orn-Arg-Oic-Pro-Gly-αMePhe-Ser-d-2-Nal-Ile), a potent B1R antagonist, is reportedly more stable than B9858 against peptidase degradation. We evaluated two radiolabeled derivatives of R954 (68Ga-HTK01083 and 18F-HTK01146) for B1R PET imaging. Peptides were synthesized via solid phase strategy. Nonradioactive standards were obtain by reacting GaCl3 with DOTA-dPEG2-R954 and by clicking N-propargyl-N,N-dimethylammoniomethyl-trifluoroborate with azidoacetyl-dPEG2-R954. Binding affinity for B1R was determined by an in vitro competition binding assay. 68Ga-HTK01083 was obtained by incubating DOTA-dPEG2-R954 with 68GaCl3 under acidic conditions, while 18F-HTK01146 was prepared via an 18F-19F isotope exchange reaction. Biodistribution and imaging studies were conducted at 1 h postinjection (p.i.) in mice inoculated with B1R-expressing (B1R+) and B1R-nonexpressing (B1R-) cells. HTK01083 and HTK01146 bound B1R with good affinity (Ki = 30.5 and 24.8 nM, respectively). 68Ga/18F-labeled R954 were obtained on average in ≥10% decay-corrected radiochemical yield with >99% radiochemical purity and ≥52 GBq/µmol specific activity. For both tracers, clearance was predominantly renal with minimal involvement of the hepatobiliary system. For PET images, B1R+ tumors, kidneys, and bladder were visible. At 1 h p.i., uptake in B1R+ tumor was comparable between 68Ga-HTK01083 (8.46 ± 1.44%ID/g) and 18F-HTK01146 (9.25 ± 0.69%ID/g). B1R+ tumor-to-blood and B1R+ tumor-to-muscle ratios were 6.32 ± 1.44 and 20.7 ± 3.58 for 68Ga-HTK01083, and 7.24 ± 2.56 and 19.5 ± 4.29 for 18F-HTK01146. Our results indicate R954 is a good lead sequence for optimization of B1R tracers for cancer imaging.
Asunto(s)
Antagonistas del Receptor de Bradiquinina B1/metabolismo , Fluorodesoxiglucosa F18/metabolismo , Radioisótopos de Galio/metabolismo , Radiofármacos/metabolismo , Receptor de Bradiquinina B1/metabolismo , Distribución Tisular/efectos de los fármacos , Animales , Línea Celular , Células HEK293 , Humanos , Masculino , Ratones , Neoplasias/diagnóstico , Neoplasias/metabolismo , Péptidos/metabolismo , Tomografía de Emisión de Positrones/métodosRESUMEN
A novel 68Ga-labeled bradykinin B1 receptor (B1R) agonist, 68Ga-Z01115, was synthesized and evaluated for imaging with positron emission tomography (PET). Z01115 exhibited good binding affinity (Ki=25.4±5.1nM) to hB1R. 68Ga-Z01115 was prepared in 74±5 decay-corrected radiochemical yield with >99% radiochemical purity and 155±89GBq/µmol (4.2±2.4Ci/µmol) specific activity. 68Ga-Z01115 was stable in vitro in mouse plasma (93% remaining intact after 60min incubation), and relatively stable in vivo (51±5% remaining intact at 5min post-injection). PET imaging and biodistribution studies in mice showed that 68Ga-Z01115 cleared rapidly from nontarget tissues/organs, and generated high target-to-nontarget contrast images. The uptake of 68Ga-Z01115 in B1R-positive (B1R+) tumor was 5.65±0.59%ID/g at 1h post-injection. Average contrast ratios of B1R+ tumor-to-B1R- tumor, -to-blood and -to-muscle were 24.3, 24.4 and 82.9, respectively. Uptake of 68Ga-Z01115 in B1R+ tumors was reduced by â¼90% with co-injection of cold standard, confirming it was mediated by B1R. Our data suggest that 68Ga-Z01115 is a promising tracer for imaging the expression of B1R that is overexpressed in a variety of cancers.
Asunto(s)
Radioisótopos de Galio , Neoplasias Experimentales/diagnóstico por imagen , Compuestos Organometálicos/análisis , Tomografía de Emisión de Positrones , Receptor de Bradiquinina B1/agonistas , Animales , Relación Dosis-Respuesta a Droga , Células HEK293 , Humanos , Ratones , Estructura Molecular , Compuestos Organometálicos/síntesis química , Compuestos Organometálicos/química , Relación Estructura-Actividad , Distribución TisularRESUMEN
Bradykinin B1 receptor (B1R), which is upregulated in a variety of malignancies, is an attractive cancer imaging biomarker. In this study we optimized the selection of radiolabel-chelator complex to improve tumor uptake and tumor-to-background contrast of radiolabeled analogues of B9958 (Lys-Lys-Arg-Pro-Hyp-Gly-Cpg-Ser-d-Tic-Cpg), a potent B1R antagonist. Peptide sequences were assembled on solid phase. Cold standards were prepared by incubating DOTA-/NODA-conjugated peptides with GaCl3, and by incubating AlOH-NODA-conjugated peptide with NaF. Binding affinities were measured via in vitro competition binding assays. (68)Ga and (18)F labeling experiments were performed in acidic buffer and purified by HPLC. Imaging/biodistribution studies were performed in mice bearing both B1R-positive (B1R+) HEK293T::hB1R and B1R-negative (B1R-) HEK293T tumors. Z02176 (Ga-DOTA-Pip-B9958; Pip: 4-amino-(1-carboxymethyl)piperidine), Z02137 (Ga-NODA-Mpaa-Pip-B9958; Mpaa: 4-methylphenylacetic acid), and Z04139 (AlF-NODA-Mpaa-Pip-B9958) bound hB1R with high affinity (Ki = 1.4-2.5 nM). (68)Ga-/(18)F-labeled peptides were obtained on average in ≥32% decay-corrected radiochemical yield with >99% radiochemical purity and 100-261 GBq/µmol specific activity. Biodistribution/imaging studies at 1 h postinjection showed that all tracers cleared rapidly from background tissues (except kidneys) and were excreted predominantly via the renal pathway. Only kidneys, bladders, and B1R+ tumors were clearly visualized in PET images. Uptake in B1R+ tumor was higher by using (68)Ga-Z02176 (28.9 ± 6.21 %ID/g) and (18)F-Z04139 (22.6 ± 3.41 %ID/g) than (68)Ga-Z02137 (14.0 ± 4.86 %ID/g). The B1R+ tumor-to-blood and B1R+ tumor-to-muscle contrast ratios were also higher for (68)Ga-Z02176 (56.1 ± 17.3 and 167 ± 57.6) and (18)F-Z04139 (58.0 ± 20.9 and 173 ± 42.9) than (68)Ga-Z02137 (34.3 ± 15.2 and 103 ± 30.2). With improved target-to-background contrast (68)Ga-Z02176 and (18)F-Z04139 are promising for imaging B1R expression in cancers with PET.
Asunto(s)
Antagonistas del Receptor de Bradiquinina B1/análisis , Tomografía de Emisión de Positrones/métodos , Radiofármacos/análisis , Receptor de Bradiquinina B1/metabolismo , Animales , Cromatografía Líquida de Alta Presión , Radioisótopos de Flúor/análisis , Radioisótopos de Galio/análisis , Células HEK293 , Humanos , Masculino , Ratones , Ratones NoqueadosRESUMEN
The neuropeptide Y1 receptor (Y1R) is overexpressed in many human cancers, particularly breast cancer. Due to stability issues, limited success has been achieved for Y1R imaging agents, including full length and truncated neuropeptide Y (NPY) analogues. The goal of this study was to evaluate the possibility of using radiolabeled truncated NPY analogues to visualize Y1R expression in a preclinical model of Y1R-positive tumor. Four truncated NPY analogues were synthesized based on the sequence of [Pro30, Tyr32, Leu34]NPY(28-36), also known as BVD15. We substituted Tyr5 and Arg6 with unnatural amino acids aiming to enhance plasma stability while maintaining good receptor binding affinity to Y1R. In addition, we substituted Leu4 to Lys4 in order to conjugate via an optional linker the DOTA chelator for 68Ga labeling. Receptor binding affinity and plasma stability of these compounds were evaluated. Positron emission tomography/computed tomography (PET/CT) imaging and biodistribution studies were performed using immune-compromised mice bearing HEK293T::WT and HEK293T::hY1R tumors. [Lys(Ga-DOTA)4, Bip5]BVD15 (CCZ01035), [Lys(Ahx-Ga-DOTA)4, Bip5]BVD15 (CCZ01053), and [Lys(Pip-Ga-DOTA)4, Bip5]BVD15 (CCZ01055) demonstrated good binding affinity to Y1R (Ki = 23.4-32.3 nM), while [Lys(Ga-DOTA)4, Har6]BVD15 (P05067) showed poor binding affinity (Ki > 1000 nM). In addition, CCZ01055 exhibited low binding affinity (Ki > 1000 nM) to Y2R and Y4R, demonstrating its selectivity to Y1R. The former three peptides showed improved in vitro plasma stability of 7-16% remaining intact after 1 h incubation. PET/CT imaging and biodistribution studies for 68Ga-labeled CCZ01053, CCZ01035, and CCZ01055 showed that radioactivity was mainly cleared by the renal pathway, and HEK293T::hY1R tumors were clearly visualized with minimal background activity with the latter two. Of these two tracers, [68Ga]CCZ01055 provided lower kidney accumulation and higher contrast, i.e., average uptake ratios of Y1R tumor to wild type tumor, blood, and muscle are 3.87 ± 0.83, 4.12 ± 1.14, and 17.6 ± 4.64, respectively. Furthermore, Y1R tumor uptake with [68Ga]CCZ01055 was significantly reduced with coinjection of 100 µg of peptide YY, confirming the specificity of tumor accumulation was receptor mediated. We successfully developed the first Y1R-targeting truncated NPY analogues for PET imaging in a preclinical model, and [68Ga]CCZ01055 is a critical template for designing improved imaging agents to detect Y1R expressing cancers.
Asunto(s)
Péptidos/química , Tomografía Computarizada por Tomografía de Emisión de Positrones/métodos , Receptores de Neuropéptido Y/metabolismo , Animales , Neoplasias de la Mama/diagnóstico por imagen , Radioisótopos de Galio , Células HEK293 , Humanos , RatonesRESUMEN
Bradykinin B1 receptor (B1R) is involved in pain and inflammation pathways and is upregulated in inflamed tissues and cancer. Due to its minimal expression in healthy tissues, B1R is an attractive target for the development of therapeutic agents to treat inflammation, chronic pain, and cancer. The goal of this study is to synthesize and compare two (18)F-labeled peptides derived from potent B1R antagonists B9858 and B9958 for imaging B1R expression with positron emission tomography (PET). Azidoacetyl-B9858 2 and azidoacetyl-B9958 3 were synthesized by a solid-phase approach and subsequently clicked to ammoniomethyl-trifluoroborate (AmBF3)-conjugated alkyne 1 to obtain AmBF3-B9858 and AmBF3-B9958, respectively. AmBF3-B9858 and AmBF3-B9958 bound B1R with high affinity, with Ki values at 0.09 ± 0.08 and 0.46 ± 0.03 nM, respectively, as measured by in vitro competition binding assays. (18)F labeling was performed via an (18)F-(19)F isotope exchange reaction. The radiofluorinated tracers were obtained within a synthesis time of 30 min and with 23-32% non-decay-corrected radiochemical yield, >99% radiochemical purity, and 43-87 GBq/µmol specific activity at the end of the synthesis. PET imaging and biodistribution studies were carried out in mice bearing both B1R-positive (B1R(+)) HEK293T::hB1R and B1R-negative (B1R(-)) HEK293T tumors. Both tracers cleared rapidly from most organs/tissues, mainly through the renal pathway. High uptake in B1R(+) tumors ((18)F-AmBF3-B9858: 3.94 ± 1.24% ID/g, tumor-to-muscle ratio 21.3 ± 4.33; (18)F-AmBF3-B9958: 4.20 ± 0.98% ID/g, tumor-to-muscle ratio 48.6 ± 10.7) was observed at 1 h postinjection. These results indicate that (18)F-AmBF3-B9858 and (18)F-AmBF3-B9958 are promising agents for the in vivo imaging of B1R expression with PET.
Asunto(s)
Calidina/análogos & derivados , Receptor de Bradiquinina B1/metabolismo , Animales , Biofarmacia , Boratos , Bradiquinina/análogos & derivados , Bradiquinina/síntesis química , Bradiquinina/química , Antagonistas del Receptor de Bradiquinina B1/síntesis química , Antagonistas del Receptor de Bradiquinina B1/química , Estabilidad de Medicamentos , Radioisótopos de Flúor , Células HEK293 , Humanos , Calidina/síntesis química , Calidina/química , Masculino , Ratones , Ratones Noqueados , Neoplasias Experimentales/diagnóstico por imagen , Tomografía de Emisión de Positrones , Radiofármacos , Distribución TisularRESUMEN
Bradykinin B1 receptor (B1R) that is overexpressed in cancers but minimally expressed in normal healthy tissues represents an attractive biomarker for the development of cancer imaging agents. The goal of this study was to evaluate the effect of different linkers on the pharmacokinetics and tumor uptake of a B1R-targeting radio-peptide sequence, 68Ga-DOTA-linker-Lys-Arg-Pro-Hyp-Gly-Cha-Ser-Pro-Leu. Four peptides, SH01078, P03034, P04115, and P04168, with 6-aminohexanoic acid, 9-amino-4,7-dioxanonanoic acid, Gly-Gly, and 4-amino-(1-carboxymethyl)piperidine, respectively, as the linker were synthesized and evaluated. In vitro competition binding assays showed that the Ki values of SH01078, P03034, P04115, and P04168 were 27.8±4.9, 16.0±1.9, 11.4±2.5, and 3.6±0.2 nM, respectively. Imaging and biodistribution studies were performed in mice bearing both B1R-positive HEK293T::hB1R and B1R-negative HEK293T tumors. All tracers showed mainly renal excretion with excellent tumor visualization and minimal background activity except for kidneys and bladder. The average uptake of 68Ga-labeled SH01078, P03034, and P04115 in HEK293T::hB1R tumor was similar (1.96-2.17%ID/g) at 1 h postinjection. 68Ga-P04168 generated higher HEK293T::hB1R tumor uptake (4.15±1.13%ID/g) and lower background activity, leading to a >2-fold improvement in HEK293T::hB1R tumor-to-background (HEK293T tumor, blood, muscle, and liver) contrasts over those of 68Ga-labeled SH01078, P03034, and P04115. Our results indicate that the choice of linker affects binding affinity, pharmacokinetics, and tumor targeting. The use of the cationic 4-amino-(1-carboxymethyl)piperidine linker improved tumor visualization, and the resulting 68Ga-P04168 might be promising for clinical application for imaging B1R-expressing tumors with positron emission tomography.
Asunto(s)
Radioisótopos de Galio/farmacocinética , Calidina/análogos & derivados , Neoplasias/metabolismo , Neoplasias/patología , Tomografía de Emisión de Positrones/métodos , Radiofármacos/farmacocinética , Receptor de Bradiquinina B1/metabolismo , Animales , Medios de Contraste/farmacocinética , Células HEK293 , Humanos , Procesamiento de Imagen Asistido por Computador , Calidina/química , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos NOD , Ratones Noqueados , Ratones SCID , Neoplasias/diagnóstico por imagen , Fragmentos de Péptidos/farmacocinética , Receptores de Interleucina-2/fisiología , Distribución Tisular , Tomografía Computarizada por Rayos XRESUMEN
(68)Ga is an attractive radiometal for use in positron emission tomography (PET) imaging. The success of (68)Ga-based agents is dependent on a chelator that exhibits rapid radiometal incorporation, and strong kinetic inertness to prevent transchelation of (68)Ga in vivo. The linear chelating agents H2dedpa (1,2-[[6-carboxypyridin-2-yl]methylamino]ethane) and H2CHXdedpa (CHX = cyclohexyl/cyclohexane) (N4O2) have recently been developed that bind Ga(3+) quickly and under mild conditions, ideal properties to be incorporated into a (68)Ga PET imaging agent. Herein, nitroimidazole (NI) derivatives of H2dedpa and H2CHXdedpa to investigate specific targeting of hypoxic tumor cells are investigated, given that NI can be reduced and retained exclusively in hypoxic cells. Nine N,N'-bis-alkylated derivatives of H2dedpa and H2CHXdedpa have been synthesized; they have been screened for their ability to bind gallium, and cyclic voltammetry of nonradioactive complexes was performed to probe the redox cycling mechanism of NI. The compounds were radiolabeled with (67)Ga and (68)Ga and show promising radiolabeling efficiencies (>99%) when labeled at 10(-5) M for 10 min at room temperature. Moreover, stability studies (via apo-transferrin challenge, 37 °C) show that the (67)Ga complexes exhibit exceptional stability (86-99% intact) after 2 h. In vitro uptake studies under hypoxic (0.5% O2) and normoxic (21% O2) conditions in three cancerous cell lines [HT-29 (colon), LCC6(HER-2) (breast), and CHO (Chinese hamster ovarian)] were performed. Of the four H2dedpa or H2CHXdedpa NI derivatives tested, all showed preferential uptake in hypoxic cells compared to normoxic cells with hypoxic/normoxic ratios as high as 7.9 ± 2.7 after 120 min. The results suggest that these novel bis-alkylated NI-containing H2dedpa and H2CHXdedpa ligands would be ideal candidates for further testing in vivo for PET imaging of hypoxia with (68)Ga.
Asunto(s)
Medios de Contraste/síntesis química , Complejos de Coordinación/síntesis química , Etilaminas/síntesis química , Radioisótopos de Galio/química , Tomografía de Emisión de Positrones/métodos , Piridinas/síntesis química , Radiofármacos/síntesis química , Animales , Células CHO , Hipoxia de la Célula , Línea Celular Tumoral , Medios de Contraste/metabolismo , Medios de Contraste/farmacología , Complejos de Coordinación/metabolismo , Complejos de Coordinación/farmacología , Cricetulus , Etilaminas/metabolismo , Etilaminas/farmacología , Humanos , Marcaje Isotópico , Ligandos , Nitroimidazoles/química , Piridinas/metabolismo , Piridinas/farmacología , Radiofármacos/metabolismo , Radiofármacos/farmacologíaRESUMEN
A novel radiofluorinated derivative of bombesin, (18)F-AmBF3-MJ9, was synthesized and evaluated for its potential to image prostate cancer by targeting the gastrin releasing peptide receptor (GRPR). AmBF3-MJ9 was prepared from an ammoniomethyl-trifluoroborate (AmBF3) conjugated alkyne 2 and azidoacetyl-MJ9 via a copper-catalyzed click reaction, and had good binding affinity for GRPR (Ki=0.5±0.1nM). The (18)F-labeling was performed via a facile one-step (18)F-(19)F isotope exchange reaction, and (18)F-AmBF3-MJ9 was obtained in 23±5% (n=3) radiochemical yield in 25min with >99% radiochemical purity and 100±32GBq/µmol specific activity. (18)F-AmBF3-MJ9 was stable in mouse plasma, and was partially (22-30%) internalized after binding to GRPR. Positron emission tomography (PET) imaging and biodistribution studies in mice showed fast renal excretion and good uptake of (18)F-AmBF3-MJ9 by GRPR-expressing pancreas and PC-3 prostate cancer xenografts. Tumor uptake was 1.37±0.25%ID/g at 1h, and 2.20±0.13%ID/g at 2h post-injection (p.i.) with low background uptake and excellent tumor visualization (tumor-to-muscle ratios of 75.4±5.5). These data suggest that (18)F-AmBF3-MJ9 is a promising PET tracer for imaging GRPR-expressing prostate cancers.
Asunto(s)
Bombesina/análisis , Radioisótopos de Flúor/análisis , Neoplasias de la Próstata/diagnóstico por imagen , Animales , Bombesina/química , Bombesina/metabolismo , Radioisótopos de Flúor/química , Radioisótopos de Flúor/metabolismo , Humanos , Masculino , Ratones , Ratones Endogámicos NOD , Ratones SCID , Tomografía de Emisión de Positrones/métodos , Neoplasias de la Próstata/metabolismo , Tomografía Computarizada por Rayos X/métodosRESUMEN
Three tertiary benzenesulfonamide inhibitors 4a-c were radiolabeled with (18)F and evaluated for imaging carbonic anhydrase IX (CA IX) expression with positron emission tomography. All three inhibitors exhibit <10 nM affinity for CA IX with no measurable affinity for CA II. Despite good affinity/selectivity to CA IX and excellent stability in plasma, uptake of [(18)F]4a-c in CA IX-expressing HT-29 tumours was low without significant contrast. [(18)F]4a,b were excreted rapidly, while [(18)F]4c exhibited significant in vivo defluorination leading to high bone uptake. Due to minimal uptake in HT-29 tumours compared to normal organs/tissues, (18)F-labeled benzenesulfonamides [(18)F]4a-c are not suitable as CA IX imaging agents.
Asunto(s)
Antígenos de Neoplasias/análisis , Inhibidores de Anhidrasa Carbónica/análisis , Inhibidores de Anhidrasa Carbónica/química , Anhidrasas Carbónicas/análisis , Neoplasias Experimentales/enzimología , Tomografía de Emisión de Positrones , Sulfonamidas/análisis , Sulfonamidas/química , Animales , Antígenos de Neoplasias/metabolismo , Anhidrasa Carbónica IX , Inhibidores de Anhidrasa Carbónica/metabolismo , Inhibidores de Anhidrasa Carbónica/farmacocinética , Anhidrasas Carbónicas/metabolismo , Radioisótopos de Flúor , Células HT29 , Humanos , Ratones , Imagen Molecular , Neoplasias Experimentales/metabolismo , Sulfonamidas/metabolismo , Sulfonamidas/farmacocinética , BencenosulfonamidasRESUMEN
Two carbonic anhydrase IX (CA IX) inhibitors were radiolabeled with (18)F, and evaluated for imaging CA IX expression. Despite good affinity for CA IX and excellent plasma stability, uptake of both tracers in CA IX-expressing HT-29 tumor xenografts in mice was low. (18)F-FEC accumulated predominately in the liver and nasal cavity, whereas a significant amount of (18)F-U-104 was retained in blood. Due to minimal uptake in HT-29 tumors compared to other organs/tissues, these two tracers are not suitable for use for CA IX-targeted imaging.
Asunto(s)
Antígenos de Neoplasias/metabolismo , Inhibidores de Anhidrasa Carbónica/síntesis química , Anhidrasas Carbónicas/metabolismo , Tomografía de Emisión de Positrones/métodos , Adenocarcinoma/diagnóstico por imagen , Animales , Anhidrasa Carbónica IX , Inhibidores de Anhidrasa Carbónica/química , Inhibidores de Anhidrasa Carbónica/farmacocinética , Inhibidores de Anhidrasa Carbónica/farmacología , Estabilidad de Medicamentos , Radioisótopos de Flúor , Células HT29 , Humanos , Ratones , Ratones Endogámicos NOD , Ratones Noqueados , Ratones SCID , Estructura Molecular , Radiofármacos , Receptores de Interleucina-2/genética , Distribución Tisular , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
A new zwitterionic organotrifluoroborate is appended to three radiosynthons that afford undergo facile bioconjugation to several clinically relevant peptides and one enzyme inhibitor. Molecularly complex bioconjugates are (18)F-labeled in a single aqueous step in rapid time (<15â min) without HPLC purification to afford tracers in good yields (>200â mCi, 20-40%) at high specific activity (≥3â Ci/µmol) and at >98% purity. PET imaging shows in vivo stability and tumor uptake.
Asunto(s)
Radioisótopos de Flúor/química , Fluorodesoxiglucosa F18/química , Marcaje Isotópico/métodosRESUMEN
To continue our efforts toward the development of (99m)Tc PiB analogs, we have synthesized 24 neutral and lipophilic Re (as a surrogate of (99m)Tc) 2-arylbenzothiazoles, and explored their structure-activity relationship for binding to Aß1-40 fibrils. These Re complexes were designed and synthesized via the integrated approach, so their (99m)Tc analogs would have a greater chance of crossing the blood-brain barrier. While the lipophilicities (logPC18=1.59-3.53) of these Re 2-arylbenzothiazoles were all within suitable range, their binding affinities (Ki=30-617nM) to Aß1-40 fibrils varied widely depending on the selection and integration of the tetradentate chelator into the 2-phenylbenzothiazole pharmacophore. For potential clinical applications, further refinement to obtain Re 2-arylbenzothiazoles with better binding affinities (<10nM) will likely be needed. The integrated approach reported here to generate compact, neutral and lipophilic Re 2-arylbenzothiazoles could be applied to other potent pharmacophores as well to convert other current Aß PET tracers to their (99m)Tc analogs for more widespread application via the use of SPECT scanners.
Asunto(s)
Péptidos beta-Amiloides/química , Complejos de Coordinación/síntesis química , Diseño de Fármacos , Fragmentos de Péptidos/química , Renio/química , Tiazoles/química , Enfermedad de Alzheimer/diagnóstico por imagen , Péptidos beta-Amiloides/metabolismo , Complejos de Coordinación/metabolismo , Humanos , Compuestos de Organotecnecio/química , Fragmentos de Péptidos/metabolismo , Unión Proteica , Radiografía , Relación Estructura-Actividad , Tiazoles/metabolismo , Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
The constant growth of the world economy and industry stimulates an increasing production of ferrous and non-ferrous metals, while the depletion of natural resources leads to demands for the development of new technologies for the processing of low-grade ores and the deep recycling of metallurgical and other anthropogenic wastes [...].
RESUMEN
Coal fly ash (CFA) obtained from pulverized coal furnaces is a highly refractory waste that can be used for alumina and rare-earth elements (REEs) extraction. The REEs in this type of CFA are associated with a mullite and amorphous glassy mass that forms a core-shell structure. In this research, it was shown that complete dissolution of amorphous aluminosilicates from the mullite surface with the formation of the low-alkali mullite concentrate prior to sulfuric acid leaching with the addition of (NH4)2SO4 helps to accelerate the extraction of REEs. The extraction degree of Sc and other REEs reaches 70-80% after 5 h of leaching at 110 °C and acid concentration of 5 M versus less than 20% for the raw CFA at the same conditions. To study the leaching kinetics of the process, the effects of temperature (90-110 °C), liquid-to-solid ratio (5-10), and leaching time (15-120 min) on the degrees of Al and rare-earth elements (REEs) extraction were evaluated. After 120 min of leaching at 110 °C and L/S ratio = 10, the extraction of Al was found to be lower than 30%. At the same time, total REEs (TREE) and Fe extraction were greater than 60%, which indicates that a part of the TREE was transferred into the acid soluble phase. After leaching, the residues were studied by laser diffraction (LD), X-ray diffraction (XRD), X-ray fluorescence (XRF), and scanning electron microscopy (SEM-EDS) to evaluate the leaching mechanism and the solubility of Al- and Fe-containing minerals, such as mullite, hematite, and amorphous aluminosilicate.
RESUMEN
Coal ash (CA) is not only one of the most solid wastes from combustion, easily resulting in a series of concerns, but it is also an artificial deposit with considerable metals, such as iron and rare earth. The variation in the coal ash characteristics due to the origins, combustion process, and even storage environment has been hindering the metal utilization from coal ash. In this study, three ash sample from lab muffle, circulating fluidized bed (CFB), and pulverized coal (PC) furnace was derived for the discrepancy study from the combustion furnace, including properties, iron, and rare earth recovery. The origins of the coal feed samples have more of an effect on their properties than combustion furnaces. Magnetic separation is suitable for coal ash from PC because of the magnetite product, and the iron content is 58% in the Mag-1 fraction, with a yield of 3%. The particles in CA from CFB appear irregular and fragmental, while those from PC appear spherical with a smooth surface. The results of sequential chemical extraction and observation both indicated that the aluminosilicate phase plays an essential role in rare earth occurrences. Rare earth in CA from muffling and CFB is facilely leached, with a recovery of approximately 50%, which is higher than that from PC ash. This paper aims to offer a reference to easily understand the difference in metal recovery from coal ash.
RESUMEN
The fusion peptide of TBEV is a short segment of the envelope protein that mediates viral and host cell membrane fusion at acidic pH. Previous studies on the E protein have shown that mutations at L107 have an effect on fusogenic activity. Structural studies have also suggested that during the fusion process the E protein rearranges to form a trimer. In the present study, a number of short peptides were synthesized, and their structure/activity was examined: (1) monomers consisting of residues 93-113 of the wild-type E protein with Leu at position 107 (WT) and two mutants, namely, L107F and L107T; (2) a monomer consisting of residues 93-113 of the E protein with a C105A mutation (TFPmn); (3) a trimer consisting of three monomers described in (2), linked at the C-terminus via 1 Lys (TFPtr); (4) a monomer consisting of residues 93-113 of the E protein plus six additional Lys at the C-terminus; and (5) a trimer consisting of three monomers described in (3), linked via the side chain of the sixth lysine. The secondary structure content of all peptides was investigated using circular dichroism (CD). Approximately seven of the residues were in beta-strand conformation, in the presence of POPC/POPE/cholesterol. The structures did not depend on pH significantly. The fusogenicity of the peptides was measured by FRET and photon correlation spectroscopy. The data suggest that TFPtr is the most fusogenic at acidic pH and that the mutation from L107 to T reduces activity. Molecular dynamics simulations of WT, L107T, and L107F suggest that this reduction in activity may be related to the fact that the mutations disrupt trimer stability. Finally, tryptophan fluorescence experiments were used to localize the peptides in the membrane. It was found that WT, L107F, TFPmn, and TFPtr could penetrate better into the acyl chain region of the lipids than the other peptides tested. The implications of these results on the fusion mechanism of TBEV E protein will be presented.
Asunto(s)
Virus de la Encefalitis Transmitidos por Garrapatas/química , Modelos Moleculares , Fragmentos de Péptidos/química , Péptidos/química , Proteínas Virales/química , Internalización del Virus , Secuencia de Aminoácidos , Simulación por Computador , Cinética , Proteínas de la Fusión de la Membrana/química , Datos de Secuencia Molecular , Conformación Proteica , Alineación de Secuencia , Homología de Secuencia de Aminoácido , Triptófano/análisisRESUMEN
Coal fly ash (CFA) is one of the most promising secondary sources of rare earth elements and yttrium (REY). This research first studied the modes of occurrence of REY in CFA collected from a China's power generation plant which utilizes a coal feedstock with an elevated REY content. The fact that rare earth minerals remain in CFA and REY associate with metal oxides was proved by emission-scanning electron microscope with an energy-dispersive X-ray spectrometer. The technical feasibility of recovery of REY from CFA was then studied through conducting various physical separation methods followed by acid leaching. It was found that REY are concentrated in fine particle size, non-magnetic and middle density fractions. Using combined physical separation processes, the REY of CFA was enriched from 782 µg·g-1to 1025 µg g-1. The acid leaching process was optimized for various parameters via the Taguchi three-level experimental design. Upon optimization, the physical separation product was leached at the optimum condition and 79.85% leaching efficiency was obtained. Based on the obtained results, a conceptual process flowsheet was developed for recovery of REY from CFA. Such recovery maximizes REY resources utilization and enhances sustainability of CFA disposal.